London Daily

Focus on the big picture.
Thursday, Jul 24, 2025

UK experts back AstraZeneca jab amid Germany ruling

UK experts back AstraZeneca jab amid Germany ruling

The prime minister and Public Health England have both defended the use of the Oxford-AstraZeneca jab, after Germany recommended that it should only be given to people aged under 65.

Dr Mary Ramsay of PHE said the jab offers "high levels of protection" against Covid-19, particularly against severe illness.

Boris Johnson said he was not concerned by Germany's recommendation.

AstraZeneca said the jab's trial data supported efficacy in the over-65s.

Germany's vaccine committee said the AstraZeneca vaccine should only be given to people aged under 65, citing a lack of sufficient data to recommend use among older age groups.

The European Medicines Agency (EMA) is to decide on Friday whether to approve the vaccine for use across the EU.

But Dr Ramsay, head of immunisations at Public Health England, said: "Both the AstraZeneca and Pfizer-BioNTech vaccines are safe and provide high levels of protection against Covid-19, particularly against severe disease.

"There were too few cases in older people in the AstraZeneca trials to observe precise levels of protection in this group, but data on immune responses were very reassuring."

Mr Johnson said he was not concerned by Germany's recommendation, adding that the UK's watchdog, the Medicines and Healthcare products Regulatory Agency (MHRA), had "made it very clear" that the AstraZeneca vaccine is "very good and efficacious" and gives a "high degree of protection after just one dose, and even more after two doses".

Speaking during a visit to Scotland, the prime minister added: "The evidence that they've supplied is that they think it is effective across all age groups [and] provides a good immune response across all age groups, so I don't agree with that [Germany's recommendation]."

An AstraZeneca spokesperson said the latest analyses of clinical trial data for its vaccine "support efficacy in the over 65 years age group", adding that the firm was awaiting "a regulatory decision on the vaccine by the EMA in the coming days".



All of the regulators and experts in different countries have been looking at the same data on the Oxford-AstraZeneca vaccine.

That data comes from clinical trials, and those did recruit fewer elderly people overall.

That's because they started off first with younger volunteers to get results as quickly as possible, given the urgency to find out if a vaccine would work well enough to help get us out of the pandemic.

The scientists who ran the trials have always been upfront about this.

But they say there is other evidence to suggest the vaccine will work well in older adults.

Studies show the over-65s have a strong immune responses to the vaccine. After receiving the shots their blood has plenty of the required antibodies that can fight coronavirus.

The UK has been using the AstraZeneca vaccine in its mass immunisation programme for weeks now and should soon have more proof from the real world setting about how much protection the shots give.

Prof Paul Hunter, of the University of East Anglia, told BBC News that the elderly should not worry about receiving the jab.

He said: "I'm almost 65 myself and I would happily take any of the vaccines, including the Oxford-AstraZeneca vaccine. We do know that it is safe in people over 65.

"They have much fewer side effects than younger people and it almost certainly provides substantial benefits in terms of preventing severe disease and reducing the chances of going into hospital."

'No concerns' over safety


Prof Adam Finn, a member of the Joint Committee on Vaccination and Immunisation (JCVI), told BBC's Radio 4's PM programme that Germany's recommendation "just reflects different levels of caution", adding: "What they are basically doing is saying 'We'd like to wait a big longer and know a bit more before we move."

Prof Finn, professor of paediatrics at the University of Bristol, said: "We have no concerns about the safety of the vaccine in any age group".

Dr Doug Brown, chief executive of the British Society for Immunology, said the MHRA would have "carefully scrutinised the evidence" on the AstraZeneca jab before making their recommendation, and referred to its original report which stated that there is "there is limited information available on efficacy in participants aged 65 or over, although there is nothing to suggest lack of protection".

He said this reflected a "need for more data" on the effectiveness of the jab in this age group, but noted the jab had shown a "good safety profile" in all published reports.

Prof Jim Naismith, director of the Rosalind Franklin Institute at the University of Oxford, said German scientists had "not said the vaccine is ineffective for over-65s".

He added: "Scientists often disagree about how much evidence is needed for any new advance and there is always more data to be secured.

"Normally this all happens out of sight of the glare of the media and not in a pandemic, but such debates are an important part of the scientific process that is familiar to anyone who has ever been through peer review."



Meanwhile, the EU and AstraZeneca are involved in a row over vaccine supply shortages.

AstraZeneca has previously said it could deliver only a fraction of the doses between January and March that it had promised to the bloc, blaming production issues at EU plants for a reported 50 million-dose shortfall.

The EU has demanded that UK-made jabs are diverted to mainland Europe to fulfil contractual obligations.

However, both sides pledged to work together to resolve the crisis.

But Cabinet Office minister Michael Gove has said there would "be no interruption" to UK vaccine supplies.

It comes as the UK recorded a further 1,239 deaths within 28 days of a positive coronavirus test on Thursday, according to government figures. There have also been another 28,680 new infections.


How does a vaccine get approved?


Newsletter

Related Articles

0:00
0:00
Close
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
×